

Auris Medical News Release

Auris Medical to Present at the 2016 Leerink Global Healthcare Conference on Thursday, February 11

Zug, Switzerland, February 5, 2016 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will webcast a live fireside chat, featuring Thomas Meyer, Chairman and CEO, at the 2016 Leerink Global Healthcare Conference on Thursday, February 11, 2015, at 8:30 a.m. EST from the Waldorf Astoria Hotel in New York. The webcast will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com).

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS".